B

디에이치엑스컴퍼니

031860KOSDAQ

61.3 / 100

Reference Date: 2026-09-08

Financial Score21.0 / 40
News Sentiment21.3 / 25
Momentum15.0 / 20
Disclosure4.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 900.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DHX Company operates diverse businesses including bicycle manufacturing, ICT distribution, biomedicine development, and regional specialty product exports, with the ICT division contributing over 90% of sales. Key products include the blood purification device 'Hemapure', AI-based brain diagnostic tool 'Neuroharmony', and immunopain treatment drug 'Afitoxin', while also conducting R&D in biocosmetics based on skin microbiome technology.

Number of Employees

27people

Average Salary

5.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
0.92Industry Average 1.204.0Point

In line with industry avg

ROE
-101.78Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
5.79Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲18.2% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -63.4% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 6,930Won52-week high 6,93052-week low 265
1-month return6.0Point

1m +900.00% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 6Negative 2
  • Neutral조회공시요구(현저한시황변동)에대한답변(미확정)2026-09-07
  • Negative주권매매거래정지기간변경 (풍문사유(현직 임원의 횡령·배임혐의설) 미해소)2026-09-07
  • Neutral조회공시요구(풍문또는보도)에대한답변(미확정)2026-09-07
  • Negative조회공시요구(풍문또는보도) (현직 임원의 횡령·배임혐의설)2026-09-04
  • Neutral대표이사변경2026-08-20